A large-scale natural history study spanning 32 years

NCT00001372, led by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), is a prospective observational cohort study that tracks the pathogenesis and organ damage processes of systemic lupus erythematosus (SLE). It began in February 1994 and is still recruiting participants at the NIH Clinical Center in Bethesda, Maryland, until 2026. The anticipated enrollment is 2,250 participants, consisting of three cohorts: SLE patients, the patients' relatives, and unrelated healthy controls. As a natural history study without drug intervention, it does not involve Phase 1, 2, or 3 clinical trials but rather a non-interventional observational study.

Design connecting genetic information and organ damage

The researchers repeatedly collect medical history, physical examinations, blood and urine samples, skin samples, and genetic information, and perform vascular function tests and cardiovascular assessments on some participants. The structure, which also analyzes the patients' first- and second-degree relatives, is advantageous for separating disease-associated variants and the effects of environment and treatment. By linking disease activity, renal and vascular complications, and drug toxicity over a long period, it is possible to validate biomarkers before and after flares, which are often difficult to capture in cross-sectional studies. The primary endpoint, the natural history of SLE, is set to be tracked until December 2050, resulting in a large amount of long-term data.

Research value compared to approved treatments

Currently, the main targets for treatment are B-cell activating factor (BAFF/BLyS), which is inhibited by Benlysta (belimumab) from GSK, and type I interferon receptor 1 (IFNAR1), which is blocked by Saphnelo (anifrolumab-fnia) from AstraZeneca. The FDA approved Benlysta on March 9, 2011, and prior to that, the Advisory Committee (AdComm) recommended approval by a vote of 13 to 2. Saphnelo was approved on July 30, 2021, for moderate-to-severe adult SLE without a separate AdComm review. For lupus nephritis, Benlysta and the calcineurin inhibitor Lupkynis (voclosporin) are approved options that compete with standard immunosuppressive therapy.

A data infrastructure asset rather than a treatment

This study does not demonstrate the efficacy of a specific candidate substance but provides a foundation that can be used for patient selection, biomarker validation, and external control design. The global SLE treatment market is projected to grow from approximately USD 2.61 billion in 2025 to USD 3.84 billion in 2031, and the ability to stratify heterogeneous patient populations is key to the success of new drugs. In particular, longitudinal data linking genotype and vascular/renal damage pathways can strengthen the human genetic basis for novel targets beyond BAFF or IFNAR1. However, individual patient data (IPD) will not be shared, and only de-identified aggregate data will be shared, which limits the scope of direct use by external companies.